Kilitch Drugs (India): Disvestment of entire stake in Material subsidiary Convert outstanding debt extended to Material subsidiary…
Kilitch Drugs (India) (KILITCH) filed a disclosure titled "Disvestment of entire stake in Material subsidiary Convert outstanding debt extended to Material subsidiary into equity shares Appointment of Additional independent non-executive…". The company is…
What happened
Kilitch Drugs (India) (KILITCH) filed a disclosure with the exchanges on 22 October 2026 at 08:18 PM titled "Disvestment of entire stake in Material subsidiary Convert outstanding debt extended to Material subsidiary into equity shares Appointment of Additional independent non-executive…".
Company snapshot
Kilitch Drugs (India) is a micro-cap company, with a market value of about ₹766 crore.
The stock last traded at ₹219, against a 52-week range of ₹117.3–₹267.9 (18.3% below the high).
Before this filing the shares had moved +16.1% over the month and +22.9% over three months. Average daily turnover over the last 20 sessions was about ₹2.33 crore.
Promoters held 63.77% at the end of Q1 FY27. Foreign institutions owned 0.12% and domestic institutions 0.00%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 43 | 3 | 1.88 |
| Q2 FY26 | 49 | 8.2 | 4.97 |
| Q3 FY26 | 54 | 4.4 | 2.5 |
| Q4 FY26 | 90 | 14.5 | 4.24 |
| Q1 FY27 | 45 | 2.9 | 0.83 |
What history shows
BCEIE has no earlier corporate update filing from this company on record since May 2026.
Market-wide, 284 corporate update filings with an impact score of 50 or more saw an average next-day move of −0.4%, with 40% rising.
Past reactions describe what happened before; they are not a forecast.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.